PNNL wins prestigious R&D 100 awards for five technologies

July 07, 2006

Richland, Wash. - The Department of Energy's Pacific Northwest National Laboratory has been recognized with five 2006 R&D 100 awards.

The R&D 100 Awards are presented annually by R&D Magazine to honor the world's 100 most important scientific and technical innovations. PNNL has now won 72 R&D 100 Awards since the magazine implemented the contest in 1963 - 65 of those have been won since 1988.

PNNL received the awards for the following technologies:

Cesium-131 Brachytherapy Seed - one of the most significant advancements in brachytherapy for cancer treatment in nearly 20 years. It is used for the treatment of prostate and other cancers, and delivers a highly targeted therapeutic dose of radiation to the tumor quickly and with potentially fewer side effects than other treatment options. PNNL shares this award with IsoRay Medical, Inc. of Richland, Wash. The technology also won a 2005 Federal Laboratory Consortium award for technology transfer.

e-RESS - a technology that improves the process for using nanoparticles in coating medical devices - such as cardiovascular stents - allowing for more consistent delivery of pharmaceutical agents and potentially reducing the need for replacement surgeries caused by the build-up of tissue. PNNL shares this award with Micell Technologies of Raleigh, N.C.

The MilliWave Thermal Analyzer - a thermal analysis instrument that uses millimeter-wave electromagnetic radiation to measure the temperature, amount of energy emitted, and physical change of materials, processes, and systems. This technology can function under extreme environments (such as very high temperatures) because contact is not required between the instrumentation and the materials; therefore, sampling of the materials is not required and the measurements can be made in real-time. PNNL shares this award with the Massachusetts Institute of Technology in Cambridge, Mass., and the Savannah River National Laboratory in Aiken, S.C.

SIM - a surface-induced mineralization technique that allows calcium-phosphate coatings enhanced with therapeutic agents to be deposited on orthopedic implants and medical devices, enhancing bone-bonding and reducing or eliminating the growth of bacteria and thereby reducing the rate of post-surgical infection. This technology also won a 2005 Federal Laboratory Consortium award for technology transfer.

Ti MIM - a technique for titanium metal injection molding that enables production of high-quality titanium metal parts for biomedical, aviation and automotive industries at lower cost, higher production rates, and better quality than existing production processes. Ti MIM is expected to be a boon for biomedical, aerospace and automotive industries.

Secretary of Energy Samuel W. Bodman noted the achievements. "I congratulate the researchers who have won these awards, which highlight the power and promise of DOE's investments in science and technology," Bodman said. "Through the efforts of dedicated and innovative scientists and engineers at our national laboratories, DOE is helping to enhance our nation's energy, economic and national security."
-end-
Members of each award-winning team will be honored in Chicago in October, at R&D Magazine's 44th annual awards banquet.

PNNL is a DOE Office of Science laboratory that solves complex problems in energy, national security, the environment and life sciences by advancing the understanding of physics, chemistry, biology and computation. PNNL employs 4,200 staff, has an annual budget of more than $725 million, and has been managed by Ohio-based Battelle since the lab's inception in 1965.

DOE/Pacific Northwest National Laboratory

Related Cancer Treatment Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

A new treatment for liver cancer
In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

NUS researchers show potential liver cancer treatment by targeting cancer stem-like cells
NUS researchers from the Cancer Science Institute of Singapore and the N.1 Institute for Health have shown the potential use of small molecule inhibitors to treat advanced liver cancer.

Breast cancer gene a potential target for childhood liver cancer treatment
Hepatoblastoma is a rare liver cancer that mainly affects infants and young children and is associated with mutations in the β-catenin gene.

Light therapy could replace opioids as main treatment for cancer treatment side effect
A worldwide coalition of researchers and clinicians has agreed that light therapy is among the most effective interventions for the prevention of oral mucositis, painful ulcers in the mouth resulting from cancer therapy.

Scanning for cancer treatment
11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019.

Visualizing better cancer treatment
Researchers have engineered nanoscale protein micelles capable of both delivering chemotherapeutic drugs and of being tracked by MRI.

Read More: Cancer Treatment News and Cancer Treatment Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.